RadNet, Inc. (RDNT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $67.13, RadNet, Inc. (RDNT) is priced for today's economics sustained for ~8.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/RDNT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 10: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.2 years.

How unusual the bet is: elevated

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.9%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.1%); the trailing year was depressed.

Bullet Takeaways

At $53.74, RadNet trades like a growth story, not the thin-margin imaging operator its current numbers describe. Trailing operating margin is about 2.9 percent and the bottom line is negative, so the price is underwriting roughly six years of margin expansion rather than today's earnings.

The split inside the company matters. Imaging Centers is a steady, cash-generating physical network; Digital Health is a fast-growing AI software business with annual recurring revenue near $97 million, up 95 percent year over year. The market is paying a software multiple for a company whose revenue is still 96 percent imaging.

The valuation methods disagree sharply. Asset and earnings-power models land in the teens because there are no current profits to capitalize; relative and forward-growth models land far higher. The gap is the bet: durable margin improvement and the Digital Health flywheel actually compounding.

Bull Case

Imaging is one of the harder sectors to value cleanly, and RadNet is the reason why. A diagnostic-imaging network looks like a low-margin physical business on the income statement, yet it sits on something scarcer: scale, referral relationships, and a multi-modality footprint that diversifies revenue and dampens reimbursement risk (FY2025 10-K, accession 0001628280-26-013337). RadNet runs the largest such network in the country. The bull case starts by accepting that the trailing 2.9 percent operating margin understates the asset, because the company is deliberately spending current profit to build a second engine on top of the first.

That second engine is Digital Health, and it changes what RadNet is. The company reports two segments, Imaging Centers and Digital Health (FY2025 10-K, accession 0001628280-26-013337), and the smaller one is growing far faster. Digital Health, run through DeepHealth, exited the first quarter of 2026 with annual recurring revenue near $97 million, up about 95 percent year over year, after the March acquisition of Gleamer made it the largest radiology-AI provider in the world by customer count. AI software attached to an installed base of imaging centers is the kind of distribution advantage a pure software competitor cannot easily replicate: RadNet owns both the scanners and the reading workflow the AI plugs into. Recurring software revenue at that growth rate, if it holds, re-rates the whole company off the thin imaging margin.

The numbers under the price reflect exactly this duration bet. Forward-growth and relative-multiple methods land well above the current price, the DCF perpetual-growth lens lands far higher still, and the EV/EBITDA frame supports the price on the strength of an adjusted-EBITDA base that grew 36 percent year over year in the first quarter to $63.3 million. The asset-value and earnings-power methods land in the teens precisely because there is no current net profit to capitalize, which is what you would expect from a company mid-investment. The bull reads that spread as the market paying for the imaging cash engine to fund the software land-grab, with management having raised full-year imaging revenue guidance and analysts carrying a Strong Buy consensus with targets clustered in the $65 to $100 range.

Bear Case

The bear case is that RadNet's moat is being defended with borrowed margin, and the erosion shows in the income statement. The imaging network's defensibility rests on scale and reimbursement diversification, but the model still earns a thin 2.9 percent operating margin and a negative bottom line, with reported ROE around negative 1.3 percent. A business that cannot consistently convert its scale into profit has a moat that protects revenue but not returns, and the data shows the returns are not there yet. Strip out the AI narrative and you are left with a capital-intensive physical operator earning less than its cost of capital.

That capital intensity is the second problem. RadNet carries real debt, including a Truist term loan with $123.75 million outstanding and other borrowings collateralized against subsidiary assets (FY2025 10-K, accession 0001628280-26-013337). Imaging centers need continuous reinvestment in scanners and facilities, so free cash flow competes with both debt service and the cash being poured into Digital Health. The Gleamer acquisition cost roughly €230 million, funded while the core business runs single-digit margins. The land-grab is being financed, and financed land-grabs only look brilliant if the new business reaches scale before the balance sheet tightens.

Third, the price assumes the Digital Health flywheel keeps spinning at near-software economics, and that assumption is the most fragile part of the thesis. Radiology AI is a crowded field, and RadNet's edge, owning the imaging base the software reads, is also a constraint: most of the addressable AI market sits at imaging centers RadNet does not own, where it competes head-on. Barclays trimmed its target to $65 even while keeping an Overweight rating, a reminder that the imaging business is the part outperforming, not the part doing the heavy lifting in the valuation. The adjusted diluted loss of $0.28 per share in the first quarter missed estimates. If Digital Health growth decelerates or its margins stay thin, the forward-growth and relative-multiple methods that justify today's price collapse toward the asset-value methods sitting in the teens.

Valuation

RadNet is a duration bet, and the valuation makes that explicit. At $53.74 (June 28, 2026) the price is not supported by anything the company earns today; it is supported by what the company is expected to become. The implied read is roughly six years of margin improvement toward about 2.1 percent on a whole-company basis, against a current operating margin near 2.9 percent and a revenue base growing in the mid-teens. That is the market pricing the imaging-plus-AI combination as a growth platform rather than a cash cow.

The methods split cleanly along that line. Forward-growth and relative-multiple lenses land above the price: relative valuation and the price-to-sales sector model both land near $111, the DCF exit-multiple lands near $69, and the margin-trajectory and discounted-future-market-cap models land in the high-$30s to high-$40s. The asset-value and earnings-power methods land in the teens or lower, because excess-return and earnings-power models have no positive current return to work with (ROE is negative and EPS is non-positive). The blended X-ray central estimate sits near $59, just above the price.

The honest framing is that none of these numbers is wrong; they are measuring different futures. If Digital Health scales into software economics, the relative and growth methods are right and the price is cheap. If the company stays a thin-margin imaging operator carrying debt, the asset methods are right and the price is a long way above fair. The valuation is a vote on which of those two stories wins.

Catalysts

First-quarter 2026 results, reported in May, set records on the top line. Revenue rose 22.1 percent year over year to $575.6 million and adjusted EBITDA rose 36.3 percent to $63.3 million, both ahead of expectations, though the company posted an adjusted diluted loss of $0.28 per share that missed on the bottom line. Management raised full-year 2026 Imaging Center revenue guidance by $30 million to a range of $2.355 billion to $2.405 billion, and reaffirmed Digital Health guidance of $135 million to $145 million in revenue.

The strategic story is the AI build-out. In March, RadNet completed the roughly €230 million acquisition of Gleamer, making its DeepHealth subsidiary the largest radiology-AI provider in the world by customer count, serving more than 2,700 customers across 44 countries. Digital Health annual recurring revenue reached about $97 million at quarter-end, up roughly 95 percent year over year. New partnerships, including a radiology-services arrangement with Saint Alphonsus Health System using DeepHealth, extend the software reach beyond RadNet's own centers.

Near-term catalysts to watch: the second-quarter print for whether imaging guidance holds and Digital Health ARR keeps its growth rate, the pace and funding of further AI acquisitions, and any progress on turning adjusted EBITDA growth into positive earnings per share. Analyst sentiment is a Strong Buy consensus with targets clustered between $65 and $100, though Barclays recently trimmed its target to $65 while keeping an Overweight rating, crediting the imaging business specifically.

Peer Cohorts (Per Segment, With Filing Citations)

Imaging Center / Digital Health (reported)

• THC (TENET HEALTHCARE CORP)
• FY2025 10-K: …imaging centers, off-campus hospital EDs and micro‑hospitals. Approximately 74% of the outpatient centers in our Hospital Operations segment at December 31, 2025 were in Arizona and Texas. Strong concentrations of facilities within operating areas may help us expand our managed care payer network, reduce management,…
• FY2025 10-K: …Hospital Indio 145 Owned San Ramon Regional Medical Center (5) San Ramon 123 JV/Owned Florida Delray Medical Center Delray Beach 536 Owned Florida Coast Medical Center Port Saint Lucie 54 Owned Good Samaritan Medical Center West Palm Beach 333 Owned Palm Beach Gardens Medical Center Palm Beach Gardens 199 Owned St.…
• SGRY (Surgery Partners, Inc.)
• FY2025 10-K: …surgery. Surgical Facilities Operations As of December 31, 2025, we owned or operated 176 surgical facilities, including 157 ASCs and 19 licensed surgical hospitals. Our Surgical Facilities contributed substantially all of our total revenue in 2025, 2024 and 2023. 1 Table of Contents Our typical ASC is a…
• FY2025 10-K: …favorable industry trends such as an aging population, advancements in medical technology and payor and government encouragement to move high acuity procedures from acute care to our lower cost sites of care will further drive growth. Total Addressable Market Based on management estimates, we believe that the total…
• HCA (HCA Healthcare, Inc.)
• FY2025 10-K: …to expand and update our facilities or acquire or construct new facilities where appropriate, enhance the provision of a comprehensive array of outpatient services, offer market competitive pricing to group purchasers of health care services, upgrade facilities and equipment and offer new or expanded programs and…
• FY2025 10-K: …2% in each federal fiscal year. CMS pools the amount collected from these reductions to fund payments to reward hospitals that meet or exceed certain quality performance standards established by CMS. CMS scores each hospital based on achievement (relative to other hospitals) and improvement (relative to the…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.